Journal of anxiety disorders · 2008
Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Donahue Christopher B, Kushner Matt G, Thuras Paul D, Murphy Tom G, Van Demark Joani B, Adson David E
Аннотация
OBJECTIVE: Clinical practice and open-label studies suggest that quetiapine (an atypical anti-psychotic) might improve symptoms for individuals with social anxiety disorder (SAD). The purpose of this study was to provide a rigorous test of the acute impact of a single dose of quetiapine (25mg) on SAD symptoms.
METHOD: Individuals with SAD (N=20) were exposed to a 4-min virtual reality (VR) public speaking challenge after having received quetiapine or placebo (double-blind) 1h earlier. A parallel VR challenge occurred 1 week later using a counter-balanced cross-over (within subject) design for the medication-placebo order between the two sessions.
RESULT: There was no significant drug effect for quetiapine on the primary outcome measures. However, quetiapine was associated with significantly elevated heart rate and sleepiness compared with placebo.
CONCLUSION: Study findings suggest that a single dose of 25mg quetiapine is not effective in alleviating SAD symptoms in individuals with fears of public speaking.
METHOD: Individuals with SAD (N=20) were exposed to a 4-min virtual reality (VR) public speaking challenge after having received quetiapine or placebo (double-blind) 1h earlier. A parallel VR challenge occurred 1 week later using a counter-balanced cross-over (within subject) design for the medication-placebo order between the two sessions.
RESULT: There was no significant drug effect for quetiapine on the primary outcome measures. However, quetiapine was associated with significantly elevated heart rate and sleepiness compared with placebo.
CONCLUSION: Study findings suggest that a single dose of 25mg quetiapine is not effective in alleviating SAD symptoms in individuals with fears of public speaking.
Предметные рубрики MeSH
Antipsychotic AgentsDepressionDiagnostic and Statistical Manual of Mental DisordersDibenzothiazepinesDisorders of Excessive SomnolenceDouble-Blind MethodDrug Administration ScheduleFemaleHeart RateHumansMalePhobic DisordersQuetiapine FumarateSeverity of Illness IndexSpeechSurveys and QuestionnairesUser-Computer InterfaceYoung Adult